Arovella Therapeutics Limited (ASX:ALA) Annual Report 2021



The latest annual report of Arovella Therapeutics Limited (ALA) was published on 30 Jun 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - ALA Annual Results

Amounts in AUD

Total Revenue
989.72k
Gross Profit
745.17k
EBIT
-3.96M
Net Tangible Assets
8.85M
Net Income
-5.05M
Capital Expenditures
-166.11k

ALA Income Statement 2021 Annual Report

As per the latest Income Statement of ALA, the Net revenue decreased by $-261705 (-21%) compared to the previous period. The operating income in 2021 increased by $109434 (3%). The net income as per the annual report was -5.05M which increased by $4.89M (49%) compared to previous year.

Income Statement Report (2021/2020)

20212020
Total Revenue989.72k1.25M
Gross Profit745.17k1.03M
Operating Income-3.96M-4.06M
Income Before Tax-5.05M-4.23M
Net Income-5.05M-9.94M

Balance Sheet - ALA 2021 Annual Report

Read further: ALA Balance Sheet Detailed Analysis

The latest balance sheet from annual result of Arovella Therapeutics Limited showed the company increased the cash on balance sheet by $5.74M (587%). The Net tangible assets of ALA on the balance sheet were at 8.85M which is $4.85M (121%) more than previous annual report. The total stockholder equity also increased by $4.85M (117%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

20212020
Cash6.72M977.47k
Total Assets10.69M 6.71M
Long Term Debt--
Total Liabilities1.71M 2.57M
Total Shareholder Equity8.98M4.14M
Net Tangible Assets8.85M4M

Cash Flow Statement - ALA 2021 Annual Report

The 2021 annual cash flow statement of Arovella Therapeutics Limited showed that the net income increased by $4.89M (49%) compared to previous reporting period. Also the capital expenditure of ALA decreased by $-25018 (-18%).

As of 2021, the total cash from investing activities was -514.55k and total cash from financing activities was 9.8M.

Cash Flow Statement Report (2021/2020)

20212020
Net Income-5.05M-9.94M
Capital Expenditures-166.11k-141.09k
Dividends Paid--
Total Cash From From Investing Activities-514.55k-388.42k
Total Cash From From Financing Activities9.8M-63.94k

Arovella Therapeutics Limited Annual Report History

Income Statement

Income Statement history of Arovella Therapeutics Limited (ASX:ALA)

30 Jun 202130 Jun 202030 Jun 201930 Jun 2018
Total Revenue989.72k1.25M1.25M486.67k
Cost Of Revenue244.55k224.58k224.69k255.92k
Gross Profit745.17k1.03M1.03M230.75k
Research Development----
Selling General Administrative1.31M1.37M1.3M1.69M
Non Recurring----
Other Operating Expenses2.7M3.05M1.61M1.85M
Total Operating Expenses4.95M5.32M3.6M3.96M
Operating Income-3.96M-4.06M-2.35M-3.48M
Total Other Income Expense Net-1.09M-166.21k-6.37M-3.3M
Ebit-3.96M-4.06M-2.35M-3.48M
Interest Expense-25.87k-14.71k-125.06k-177.03k
Income Before Tax-5.05M-4.23M-8.72M-6.78M
Income Tax Expense---925k-745k
Minority Interest----
Net Income From Continuing Ops-5.05M-4.23M-7.8M-6.03M
Discontinued Operations--5.7M-5.7M573.8k
Extraordinary Items----
Effect Of Accounting Charges----
Other Items----
Net Income-5.05M-9.94M-7.8M-5.46M
Net Income Applicable To Common Shares-5.05M-9.94M-7.8M-5.46M

Balance Sheet Statement

Balance Sheet Statement history of Arovella Therapeutics Limited (ASX:ALA)

30 Jun 202130 Jun 202030 Jun 201930 Jun 2018
Cash6.72M977.47k4.31M98.12k
Net Receivables534.31k989.49k1.17M790.73k
Total Current Assets7.34M2.03M5.6M1.07M
Property Plant Equipment432.94k421.63k367.37k172.69k
Intangible Assets132.36k132.36k132.36k-
Other Assets2.78M4.12M10.16M15.4M
Total Assets10.69M6.71M16.25M16.64M
Accounts Payable227.46k732.07k480.4k352.56k
Other Current Liab1.2M1.03M701.01k1.42M
Other Liab7.91k545.36k910.35k1.32M
Deferred Long Term Liab2.78M4.12M10.16M15.4M
Total Current Liabilities1.69M2.02M1.35M3.84M
Total Liab1.71M2.57M2.28M5.18M
Common Stock77M67.39M67.39M57.2M
Retained Earnings-68.47M-64.88M-55.71M-47.92M
Treasury Stock450.69k1.63M2.3M2.18M
Other Stockholder Equity450.69k1.63M2.3M2.18M
Total Stockholder Equity8.98M4.14M13.98M11.46M
Net Tangible Assets8.85M4M13.85M11.46M
Long Term Debt----

Cash Flow Statement

Cash Flow Statement history of Arovella Therapeutics Limited (ASX:ALA)

30 Jun 202130 Jun 202030 Jun 201930 Jun 2018
Net Income-5.05M-9.94M-7.8M-5.46M
Depreciation203.18k222.97k121.72k98.46k
Change To Netincome1.31M5.97M6.47M136.39k
Change To Account Receivables335.53k251.34k-330.14k42.4k
Change To Liabilities-453.24k564.51k-1.36M2.57M
Change To Operating Activities-339.44k-311.03k84.23k-23.41k
Total Cash From Operating Activities-3.54M-2.88M-2.5M-2.55M
Capital Expenditures-166.11k-141.09k-312.71k-68.31k
Total Cashflows From Investing Activities-514.55k-388.42k-1.38M676.34k
Net Borrowings-57.58k-63.94k-63.94k200k
Other Cashflows From Financing Activities-724.49k-724.49k-724.49k-724.49k
Total Cash From Financing Activities9.8M-63.94k8.1M200k
Change In Cash5.74M-3.34M4.22M-1.67M
Issuance Of Stock10.58M10.58M8.1M8.1M
Dividends Paid----